Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
What it isnt: A primary care prescriber leaving you on the same Ozempic dose for a year and hoping the scale moves
They do not measure medication strength
30.3% at 104 weeks in a BMI 35 extension cohort TRANSCEND-T2D-1 confirmed (topline March 2026, published June 2026): First completed diabetes-specific Phase 3 trial -2.0% HbA1c and 16.8% weight loss in 537 patients, a separate program from TRIUMPH Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic now expected Q1 2027 (shifted from the previously estimated Q4 2026) OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour This page updates after every trial announcement bookmark for the latest Introduction Retatrutide stands at the forefront of obesity medicine a first-in-class triple hormone agonist that has demonstrated some of the highest weight loss efficacy ever recorded in clinical trials
From there, your provider may increase the dose in 2.5mg increments every four weeks based on response and tolerability
High-protein meal strategies that supported your GLP-1 treatment translate directly to your maintenance phase
US$ 28.99
US$ 29.66
US$ 21.45
US$ 25.87
